SGP serves as a structural protein in ebola virus infection

Journal of Infectious Diseases

Volumn 204, Issue SUPPL. 3, 2011, Pages

  Iwasa, Ayaka ^a   Shimojima, Masayuki ^c   Kawaoka, Yoshihiro ^a,b,d,e  

^a Division of Virology   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c YAMAGUCHI UNIVERSITY   (Japan)

^d JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^e UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; GLYCOPROTEIN 1; GLYCOPROTEIN 2; GREEN FLUORESCENT PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN; KZ52 ANTIBODY; PROTEIN VP40; SECRETORY GLYCOPROTEIN; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS NUCLEOPROTEIN; VIRUS PROTEIN;

AMINO ACID SEQUENCE; ANIMAL CELL; COMPLEX FORMATION; CONFERENCE PAPER; CONTROLLED STUDY; EBOLA VIRUS; EBOLA VIRUS INFECTION; FILOVIRUS INFECTION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; NONHUMAN; PATHOPHYSIOLOGY; PLASMID; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PSEUDOTYPING; REPORTER GENE; VIRUS INFECTIVITY; VIRUS LIKE AGENT; VIRUS NEUTRALIZATION; WESTERN BLOTTING; ZAIRE EBOLAVIRUS;

ANIMALS; ANTIBODIES, VIRAL; BLOTTING, WESTERN; CERCOPITHECUS AETHIOPS; EBOLAVIRUS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, VIRAL; GLYCOPROTEINS; HEK293 CELLS; HUMANS; MEMBRANE GLYCOPROTEINS; PLASMIDS; VERO CELLS; VIRAL PROTEINS; VIRAL STRUCTURAL PROTEINS;

EID: 80054763212     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir313     Document Type: Conference Paper

References (35)

1. Sanchez A, Trappier SG, Mahy BW, Peters CJ, Nichol ST. The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc Natl Acad Sci U S A 1996; 93:3602-7. (Pubitemid 26125667)
2. Volchkov VE, Feldmann H, Volchkova VA, Klenk HD. Processing of the Ebola virus glycoprotein by the proprotein convertase furin. Proc Natl Acad Sci U S A 1998; 95:5762-7.
3. Volchkova VA, Klenk HD, Volchkov VE. Delta-peptide is the carboxyterminal cleavage fragment of the nonstructural small glycoprotein sGP of Ebola virus. Virology 1999; 265:164-71. (Pubitemid 30012395)
4. Sanchez A, Yang ZY, Xu L, Nabel GJ, Crews T, Peters CJ. Biochemical analysis of the secreted and virion glycoproteins of Ebola virus. J Virol 1998; 72:6442-7. (Pubitemid 28323957)
5. Barrientos LG, Martin AM, Rollin PE, Sanchez A. Disulfide bond assignment of the Ebola virus secreted glycoprotein SGP. Biochem Biophys Res Commun 2004; 323:696-702. (Pubitemid 39221151)
6. Falzarano D, Krokhin O, Wahl-Jensen V, et al. Structure-function analysis of the soluble glycoprotein, sGP, of Ebola virus. Chembiochem 2006; 7:1605-11. (Pubitemid 44556008)
7. Ito H, Watanabe S, Sanchez A, Whitt MA, Kawaoka Y. Mutational analysis of the putative fusion domain of Ebola virus glycoprotein. J Virol 1999; 73:8907-12. (Pubitemid 29441763)
8. Wahl-Jensen VM, Afanasieva TA, Seebach J, Ströher U, Feldmann H, Schnittler HJ. Effects of Ebola virus glycoproteins on endothelial cell activation and barrier function. J Virol 2005; 79:10442-50. (Pubitemid 41098584)
9. Yang Z, Delgado R, Xu L, et al. Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins. Science 1998; 279:1034-7. (Pubitemid 28113305)
10. Kindzelskii AL, Yang Z, Nabel GJ, Todd RF 3rd, Petty HR. Ebola virus secretory glycoprotein (sGP) diminishes Fc gamma RIIIΒ-to-CR3 proximity on neutrophils. J Immunol 2000; 164:953-8. (Pubitemid 30043722)
11. Sui J, Marasco WA. Evidence against Ebola virus sGP binding to human neutrophils by a specific receptor. Virology 2002; 303:9-14. (Pubitemid 36027161)
12. Takada A, Robison C, Goto H, et al. A system for functional analysis of Ebola virus glycoprotein. Proc Natl Acad Sci U S A 1997; 94:14764-9. (Pubitemid 28041448)
13. Wool-Lewis RJ, Bates P. Characterization of Ebola virus entry by using pseudotyped viruses: identification of receptor-deficient cell lines. J Virol 1998; 72:3155-60. (Pubitemid 28175558)
14. Chan SY, Speck RF, Ma MC, Goldsmith MA. Distinct mechanisms of entry by envelope glycoproteins of Marburg and Ebola (Zaire) viruses. J Virol 2000; 74:4933-7. (Pubitemid 30237927)
15. Jeffers SA, Sanders DA, Sanchez A. Covalent modifications of the ebola virus glycoprotein. J Virol 2002; 76:12463-72. (Pubitemid 35386932)
16. Manicassamy B, Wang J, Jiang H, Rong L. Comprehensive analysis of ebola virus GP1 in viral entry. J Virol 2005; 79:4793-805. (Pubitemid 40464230)
17. Kuhn JH, Radoshitzky SR, Guth AC, et al. Conserved receptor-binding domains of Lake Victoria marburgvirus and Zaire ebolavirus bind a common receptor. J Biol Chem 2006; 281:15951-8. (Pubitemid 43848488)
18. Brindley MA, Hughes L, Ruiz A, et al. Ebola virus glycoprotein 1: identification of residues important for binding and postbinding events. J Virol 2007; 81:7702-9. (Pubitemid 47047855)
19. Lee JE, Fusco ML, Hessell AJ, Oswald WB, Burton DR, Saphire EO. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 2008; 454:177-82. (Pubitemid 351969896)
20. Dube D, Brecher MB, Delos SE, et al. The primed ebolavirus glycoprotein (19-kilodalton GP1,2): sequence and residues critical for host cell binding. J Virol 2009; 83:2883-91.
21. Volchkov VE, Volchkova VA, Slenczka W, Klenk HD, Feldmann H. Release of viral glycoproteins during Ebola virus infection. Virology 1998; 245:110-9. (Pubitemid 28384082)
22. Maruyama T, Rodriguez LL, Jahrling PB, et al. Ebola virus can be effectively neutralized by antibody produced in natural human infection. J Virol 1999; 73:6024-30. (Pubitemid 29274889)
23. Takada A, Ebihara H, Feldmann H, Geisbert TW, Kawaoka Y. Epitopes required for antibody-dependent enhancement of Ebola virus infection. J Infect Dis 2007; 196:S347-56. (Pubitemid 351417281)
24. Niwa H, Yamamura K, Miyazaki J. Efficient selection for highexpression transfectants with a novel eukaryotic vector. Gene 1991; 108:193-200.
25. Kobasa D, Rodgers ME, Wells K, Kawaoka Y. Neuraminidase hemadsorption activity, conserved in avian influenza A viruses, does not influence viral replication in ducks. J Virol 1997; 71:6706-13. (Pubitemid 27355330)
26. Mühlberger E, Weik M, Volchkov VE, Klenk HD, Becker S. Comparison of the transcription and replication strategies of Marburg virus and Ebola virus by using artificial replication systems. J Virol 1999; 73:2333-42. (Pubitemid 29098138)
27. Watanabe S, Watanabe T, Noda T, et al. Production of novel ebola virus-like particles from cDNAs: an alternative to ebola virus generation by reverse genetics. J Virol 2004; 78:999-1005. (Pubitemid 38067621)
28. Licata JM, Johnson RF, Han Z, Harty RN. Contribution of ebola virus glycoprotein, nucleoprotein, and VP24 to budding of VP40 virus-like particles. J Virol 2004; 78:7344-51. (Pubitemid 38915880)
29. Johnson RF, Bell P, Harty RN. Effect of Ebola virus proteins GP, NP and VP35 on VP40 VLP morphology. Virol J 2006; 3:31.
30. Volchkova VA, Feldmann H, Klenk HD, Volchkov VE. The nonstructural small glycoprotein sGP of Ebola virus is secreted as an antiparallel-orientated homodimer. Virology 1998; 250:408-14. (Pubitemid 28489640)
31. Shedlock DJ, Bailey MA, Popernack PM, Cunningham JM, Burton DR, Sullivan NJ. Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms. Virology 2010; 401:228-35.
32. Mpanju OM, Towner JS, Dover JE, Nichol ST, Wilson CA. Identification of two amino acid residues on Ebola virus glycoprotein 1 critical for cell entry. Virus Res 2006; 121:205-14. (Pubitemid 44467987)
33. Yang ZY, Duckers HJ, Sullivan NJ, Sanchez A, Nabel EG, Nabel GJ. Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat Med 2000; 6:886-9. (Pubitemid 30644746)
34. Feldmann H, Volchkov VE, Volchkova VA, Klenk HD. The glycoproteins of Marburg and Ebola virus and their potential roles in pathogenesis. Arch Virol Suppl 1999; 15:159-69.
35. Volchkov VE, Volchkova VA, Muhlberger E, et al. Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity. Science 2001; 291:1965-9. (Pubitemid 32216997)